INTRODUCTION: Infliximab (IFX) therapy intensification in @entity31 ( @entity31 ) is more common than established in pivotal studies. OBJECTIVES: To establish the frequency and form of intensification for @entity31 in clinical practice, as well as predictors, and to compare outcomes between intensified and non-intensified treatment. METHODS: A retrospective study of 10 hospitals and 144 @entity1 with response to infliximab (IFX) induction. Predictive variables for intensification were analyzed using a Cox regression analysis. Outcome, loss of response to IFX, and colectomy were compared between intensified and non-intensified therapy. RESULTS: Follow-up time from induction to data collection: 38 months [interquartile range (IQR), 20-62]. Time on IFX therapy: 24 months (IQR, 10-44). In all, 37% of @entity1 required intensification. Interval was shortened for 36 @entity1 , dose was increased for 7, and 10 subjects received both. Concurrent @entity10227 immunosuppressants (IMM) and IFX initiation was an independent predictor of intensification [Hazard ratio, 0.034; p, 0.006; CI, 0.003-0.371]. In @entity1 on intensified therapy IFX discontinuation for loss of response (30.4% vs. 10.2%; p, 0.002), @entity479 reintroduction (35% vs. 18%; p, 0.018), and colectomy (22% vs. 6.4%; p, 0.011) were more common. Of @entity1 on intensification, 17% returned to receiving 5 mg/kg every 8 weeks. CONCLUSIONS: Intensification is common and occasionally reversible. IMM initiation at the time of induction with IFX predictsnon-intensification. Intensification, while effective, is associated with poorer outcome.

Frequency, predictors, and consequences of maintenance infliximab therapy intensification in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis', 'UC'] @entity479 :: ('D013256', 'Chemical') :: ['steroid'] @entity10227 :: ('CHEBI:35666', 'Chemical') :: ['thiopurine']
@entity31 :: (MESH:D003093,Disease) :: ['ulcerative colitis']
